# Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

> **NCT01423149** · PHASE2 · COMPLETED · sponsor: **Mateon Therapeutics** · enrollment: 23 (actual)

## Conditions studied

- Choroidal Neovascularization
- Myopia, Degenerative

## Interventions

- **DRUG:** Combretastatin A-4 Phosphate

## Key facts

- **NCT ID:** NCT01423149
- **Lead sponsor:** Mateon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2011-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423149, "Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01423149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*